



SUPPLEMENT APPROVAL

Our STN: BL 125254/718

Seqirus Pty Ltd
Attention: Kelly T. Boyle
Biologics Consulting Group, Inc.
1555 King Street, Suite 300
Alexandria, VA 22314

July 13, 2018

Dear Ms. Boyle:

We have approved your request dated May 1, 2018, to supplement your Biologics License Application submitted under section 351(a) of the Public Health Service Act (42 U.S.C. 262) for Influenza Vaccine (Afluria® and Afluria® Quadrivalent) manufactured at your Marburg, Germany and Kankakee, IL facilities to include the 2018-2019 United States formulation and associated labeling revisions.

LABELING

We hereby approve the draft package insert labeling submitted May 1, 2018, and the draft carton and container labeling submitted May 1, 2018, and the draft carton label submitted under Amendment 4 dated June 29, 2018.

Please provide your final content of labeling including the carton and container labels in Structured Product Labeling (SPL) format. All final labeling should be submitted as Product Correspondence to BLA STN 125254 at the time of use (prior to marketing) and include implementation information on Form FDA 356h.

In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely yours,

Jerry P. Weir, Ph.D.
Director
Division of Viral Products
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research